Pattern of HIV-1 Drug Resistance among Adults on ART in Nigeria

Georgina N. Odaibo, Prosper Okonkwo, Isaac F. Adewole, David O. Olaleye

AIDS Prevention Initiative Nigeria, Arab Contractor Building, Abuja, Nigeria.
Department of Obstetrics and Gynecology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Department of Virology, College of Medicine, University of Ibadan, Ibadan, Nigeria.

DOI: 10.4236/wja.2013.34042                

Abstract

Background: The development of anitiretroviral drug resistance may limit the benefit of antiretroviral therapy. Therefore the need to closely monitor these mutations, especially the use of ART is increasing. This study was therefore designed to determine the ARV drug resistance pattern among ART na?ve and expose individuals attending a PEPFAR supported by antiretroviral clinic in Nigeria. Methodology: The study participants included patients attending the PEPFAR supported by University College Hospital (UCH), Ibadan ART clinic who have been on HIV treatment for at least one year with consecutive viral load of over 2000 copies/ml as well some ART Na?ve individuals with high (>50,000 copies/ml) baseline viral level attending the hospital for pre-ART assessment. Blood sample was collected from each individual for CD4 enumeration, viral load level determination and DNA sequencing for genotypic typing. Antiretroviral drug resistance mutations (DRM) were determined by using the Viroseq software and drug mutations generated by using a combination of Viroseq and Stanford algorithm. DRM were classified as major or minor mutations based on the June 2013 Stanford DR database. Results: The most common major NRTI, NNRTI and PI mutation were D67N (33.3%), Y181C (16.7%) and M46L/I (55.6%) respectively. Lamivudine (3TC) and emtricitabine (FTC); nevirapine (NVP) and nelfinavir (NFV) were the most common NRTI, NNRTI, and PI drugs to which the virus in the infected individuals developed resistance. Isolates from 4 patients were resistant to triple drug class, including at least one NRTI, NNRTI and a PI. Only one (4.8%) of the isolates from drug Na?ve individuals had major DRM that conferred resistance to any drug. Conclusion: Demonstration of high rates of antiretroviral DRM among patients on 1^st and 2^nd line ART and the presence of DRM in drug Na?ve individuals in this study show the importance of surveillance for resistance to ARV in line with the magnitude of scaling up of treatment program in the country.

Keywords

Antiretroviral Therapy; Drug Resistance Mutation; ART Naïve; 1st and 2nd Line ART

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	S. Robert, S. M. Gottlieb, M. H. Schanker, D. Joel, D. O. Weisman, F. P. Thim, A. R. Wolf and S. Andrew, “Pnuemocystiscarinii Pnuemoniaand Mucosal Candidiasis in Previously Healthy Homosexual Men—Evidence of a new Acquire Cellular Immunodeficiency,” New England Journal of Medicine, Vol. 305, 1981, pp. 1425-1431. http://dx.doi.org /10.1056 /NEJM198112103052401
[2]	UNAIDS, “State of the Epidemic,” Report of the Global AIDS Epidemic, 2012, pp. 1-103. http://www.unaids.org /en/media/unaids/contentassets /documents/epidemiology/2012/gr2012 /20121120_UNAIDS_Global_Report_ 2012_with_annexes_en.pdf
[3]	FMOH, “National HIV Sero-Prevalence Sentinel Survey among Pregnant Women Attending Antenatal Clinics in Nigeriam,” Technical Report, 2010, pp. 1-96.
[4]	S. M. Hammer, J. J. Eron Jr., P. Reiss, et al., “Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel,” JAMA, Vol. 300, No. 5, 2008, pp. 555-570. http://dx.doi.org/10.1001/jama.300.5.555
[5]	World Health Organization, UNAIDS and UNICEF, “Towards Universal Assess: Scaling up Priority HIV/AIDS Interventions in the Health Sector,” 2010.
[6]	G. Panos, G. Samonis, V. G. Alexiou, G. A. Kavarnou, G. Charatsis and M. E. Falagas, “Mortality and Mobidity of HIV-Infected Patients Receiving HAART: A Cohort Study,” Current HIV Research, Vol. 6, No. 3, 2008, pp. 257-260. http://dx.doi.org/10.2174/157016208784324976
[7]	P. Severe, P. Leger, M. Charles, et al., “Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti,” New England Journal of Medicine, Vol. 353, No. 32, 2005, pp. 2325-2334. http://dx.doi.org/10.1056/NEJMoa051908
[8]	P. E. Sax, R. Islam, R. P. Walensky, et al., “Should Resistance Testing Be Performed for Treatment-Naïve HIVInfected Patients? A Cost-Effectiveness Analysis,” Clinical Infectious Diseases, Vol. 41, No. 9, 2005, pp. 1316-1323. http://dx.doi.org/10.1086/496984
[9]	A. Mocroft, S. Vella, T. Benifield, et al., “Charging Patterns of Mortality Across Europe in Patients Infected with HIV-1,” Lancet, Vol. 352, No. 9142, 1998, pp. 1725-1730. http://dx.doi.org/10.1016/S0140-6736(98)03201-2
[10]	J. Marins, L. Jamal, S. Chen, et al., “Dramatic Improvement in Survival among Adult Brazilian AIDS Patients,” AIDS, Vol. 17, No. 11, 2003, pp. 1675-1682. http://dx.doi.org/10.1097/00002030-200307250-00012
[11]	J. Peterson and O. Obileye, “Access to Drugs for HIV/ AIDS and Related Opportunistic Infections in Nigeria,” POLICY Project, Nigeria, 2002.
[12]	O. Odutolu, B. A. Ahonsi, M. Gboun and O. M. Jolayemi, “The National Response to HIV/AIDS,” In: O. Adeyi, P. H. Kanki, O. Odutolu and J. A. Idoko, Eds., AIDS in Nigeria: “A Nation on a Threshold”, Harvard University Press, Cambridge, 2006, pp. 241-279.
[13]	C. Wallis, M. Papthanasopoulos, M. Fox, et al., “Lows Rate of Nucleoside Reverse Transcriptase Inhibitor (NRTI) Resistant Detected in a Well Monitored Cohort in South Africa Accessing Antiretroviral Therapy,” Antiviral Therapy, Vol. 17, No. 2, 2012, pp. 313-320. http://dx.doi.org/10.3851/IMP1985
[14]	V. C. Marconi, H. Sunpath, Z. G. Lu, M. Gordon, K. Koranteng-Apeagyei, J. Hampton, S. Carpentar, et al., “Prevalence of HIV-1 Drug Resistance After Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa,” Clinical Infectious Diseases, Vol. 46, No. 10, 2008, pp. 1589-1597. http://dx.doi.org/10.1086/587109
[15]	H. Hatano, P. Hunt, J. Weidler, et al., “Rate of Vira Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen,” Clinical Infectious Diseases, Vol. 43, No. 10, 2006, pp. 1329-1336. http://dx.doi.org/10.1086/508655
[16]	Nigeria’s HIV/AIDS Information Website, “Current HIV/ AIDS Statistics in Nigeria.” www.nigeriahivinfo.com
[17]	R. E. Nettles, T. L. Kieffer, R. P. Simmons, et al, “Genotypic Resistant in HIV-1-infcted Patients with Persistently Detectable Low Level Viremia While Receiving Highly Active Antiretroviral Therapy,” Clinical Infectious Diseases, Vol. 39, No. 7, 2004, pp. 1030-1037. http://dx.doi.org/10.1086/423388
[18]	S. Palmer, M. Kearney, F. Maldarelli, et al., “Multiple, Linked Human Immunodeficiency Virus Type Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis,” Journal of Clinical Microbiology, Vol. 43, No. 1, 2005, pp. 406-413. http://dx.doi.org/10.1128/JCM.43.1.406-413.2005
[19]	F. Doualla-Bell, T. Gaolathe, A. Avalos, et al., “Five Years Follow Up of Genotypic Resistance Patterns in HIV-1 Subtype C Infected Patients in Botswana after Failure of Thymidine Analogue-Based Regimens,” Journal of the International AIDS Society, Vol. 12, 2009, p. 25. http://dx.doi.org/10.1186/1758-2652-12-25
[20]	E. O. Idigbe, T. A. Adewole, G. Eisie, et al., “Management of HIV-1 Infection with a Combination of Nevirapine, Stavudine, and Lamivudine: A Preliminary Report on Nigerian Antiretroviral Program,” Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 1, 2005, pp. 65-69. http://dx.doi.org/10.1097/01.qai.0000159516.39982.1b
[21]	J. E. Gallant, A. E. Rodriguez, W. G. Weinberg, et al., “Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV-Infected Antiretroviral-Naïve Subjects,” Journal of Infectious Diseases, Vol. 192, No. 11, 2005, pp. 921-930. http://dx.doi.org/10.1086/498069
[22]	World Health Organization, “HIV Drug Resistance Report,” 2012, pp. 3-78.
[23]	D. R. Kuritzkes, “Extending Antiretroviral Therapy to Resource-Poor Settings: Implications for Drug Resistance,” AIDS, Vol. 18, Suppl. 3, 2004, pp. S45-S48. http://dx.doi.org/10.1097/00002030-200406003-00009
[24]	J. M. Lang, J. Perriens, D. Kuritzkes and D. Zewdie, “What Policymakers Should Know about Drug Resistance and Adherence in the Context of Scaling-Up Treatment of HIV Infection,” AIDS, Vol. 18, Suppl. 13, 2004, pp. 569-574.
[25]	B. Chaplin, G. Eisen, J. Idoko, D. Onwujekwe, E. Idigbe, I. Adewole, W. Gashau, S. Meloni, A. D. Sarr, J. L. Sankalé, E. Ekong, R. L. Murphy and P. Kanki, “Impact of HIV Type 1 Subtype on Drug Resistance Mutations in Nigerian Patients Failing First-Line Therapy,” AIDS Research and Human Retroviruses, Vol. 27, No. 1, 2011, pp. 71-80. http://dx.doi.org/10.1089/aid.2010.0050
[26]	G. N. Odaibo, S. O. Ola, M. Landerz, U. Dietrich and D. O. Olaleye, “HIV-1 Drug Resistant Mutations in Chronically Infected Treatment Naive Individuals in the PreARV Era in Nigeria,” African Journal of Medicine & Medical Sciences, Vol. 41, 2012, pp. 61-63.
[27]	A. M. J. Wensing, D. A. van de Vijver, G. Angarano, et al., “Prevalence of Drug-Resistance HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management,” Journal of Infectious Diseases, Vol. 192, No. 6, 2005, pp. 958-966. http://dx.doi.org/10.1086/432916
[28]	D. Paraskevis, E. Magiokinis, A. Katsoulidou, et al., “Prevalence of Resistance-Associated Mutations in Newly Diagnosed HIV-1 Patients in Greece,” Virus Research, Vol. 112, No. 1, 2005, pp. 115-122. http://dx.doi.org/10.1016/j.virusres.2005.03.004
[29]	S. J. Litle, S. Holte, J. P. Routy, et al., “Antiretroviral-Drug Resistance among Patients Recently Infected with HIV,” New England Journal of Medicine, Vol. 347, 2002, pp. 385-394. http://dx.doi.org/10.1056/NEJMoa013552
[30]	R. L. Hamers, K. C. Sigaloff, A. M. Wensing, L. C. Wallis, C. KItyo, M. Siwale, K. Mandaliya, et al., “Patterns of HIV-1 Drug Resistance after First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies,” Clinical Infectious Diseases, Vol. 54, No. 11, 2012, pp. 1660-1669.
[31]	S. Jallow, A. Alabi, R. Sarge-Njie, K. Peterson, H. Whittle, et al., “Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in the Gambia and Emergence of Drug Resistant Variants,” Journal of Clinical Microbiology, Vol. 47, No. 7, 2009, pp. 2200-2208. http://dx.doi.org/10.1128/JCM.01654-08
[32]	E. A. Abar, A. Jlizi, Y. H. Darar, et al., “HIV-1 Drug Resistance Genotyping from Antiretroviral Therapy (ART) Na?ve and First-Line Treatment Failures in Djiboutian Patients,” Diagnostic Pathology, Vol. 7, 2012, p. 138. http://dx.doi.org/10.1186/1746-1596-7-138
[33]	V. Novitsky, C. W. Wester, V. DeGruttola, et al., “The Reverse Transcriptate 67N 70R 215Y Genptype Is the Predominant TAM; Athway Associated with Virologic Failure among HIV Type 1C-Infected Adults Treated with ZDV/ddl-Containing HAART in Southern Africa,” AIDS Research and Human Retroviruses, Vol. 23, 2007, pp. 868-878. http://dx.doi.org/10.1089/aid.2006.0298
[34]	J. Liu, J. Yue, S. Wu and Y. Yan, “Polymorphisms and Drug Resistance Analysis of HIV-1 CRF01_AE Strains Circuiting in Fujian Province, China,” Archives of Virology, Vol. 152, No. 10, 2007, pp. 1799-1805. http://dx.doi.org/10.1007/s00705-007-1019-9
[35]	UK Group on Transmitted HIV Drug Resistance, “Time Trends in Primary Resistance HIV Drugs in the United Kingdom: Multicenter Observational Study,” British Medical Journal, Vol. 331, No. 7529, 2005, pp. 1368-1373. http://dx.doi.org/10.1136/bmj.38665.534595.55
[36]	N. A. Ingole, S. M. Kukreja and P.-R. Mehata, “Role of HIV-1 Viral Load in Initiating Antiviral Therapy,” World Journal of AIDS, Vol. 1, No. 4, 2011, pp. 149-154. http://dx.doi.org/10.4236/wja.2011.14022
[37]	WHO, “Clinical and Laboratory Monitoring of Antiretroviral Therapy in Resource-Limited and Unlimited Settings,” HIV/AIDS Antiretroviral Newsletter, No. 4, 2000, pp. 1-4.
[38]	S. P. Eholie, C. C. T. N’Dour, M. Cisse, E. Bissagnene and P. M. Girad, “Observance of Antiretroviral Treatments African Specificities,” Médecine et Maladies Infectieuses, Vol. 36, 2006, pp. 443-448.
[39]	B. Shah, L. Walshe, D. G. Saple, et al., “Adherence to Antiretroviral Therapy and Virologic Suppression among HIV-Infected Persons Receiving Care in Private Clinics in Mumbai, India,” Clinical Infectious Diseases, Vol. 44, No. 9, 2007, pp. 1235-1244. http://dx.doi.org/10.1086/513429
[40]	A. M. Geretti, C. Smith, A. Haberl, et al., “Determinants of Virological Failure after Successful Viral Load Suppression in First-Line Highly Active Antiretroviral Therapy,” Antiviral Therapy, Vol. 13, No. 7, 2008, pp. 927-936.
[41]	M. A. Chesney, J. Ickovics, F. M. Hecht, et al., “Adherence: A Necessity of Successful HIV Combination Therapy,” AIDS, Vol. 13, Suppl. A, 1999, pp. S271-S278.
[42]	A. J. Leigh Brown, S. D. Frost, W. C. Matthews, et al., “Transmission Fitness of Drug-Resistant Human Immunodeficiency Virus and the Prevalence of Resistance in the Antiretroviral-Treated Population,” Journal of Infectious Diseases, Vol. 187, No. 4, 2003, pp. 683-686. http://dx.doi.org/10.1086/367989
[43]	A. Fibrian, R. Wisaksana, A. Indrati, Y. Hartantri, et al., “Virology Failure and Drug Resistance during First Line Antiretroviral Treatment in Indolnesia,” Journal of Medical Virology, Vol. 85, No. 8, 2013, pp. 1394-1401. http://dx.doi.org/10.1002/jmv.23606
[44]	M. Vidya, S. Saravana, S. Uma, N. Kumarasamy, et al., “Genotypic HIV Type 1 Drug Resistance among Patients with Immunological Failure to First Line Antiretroviral Therapy on South India,” Antiviral Therapy, Vol. 14, No. 7, 2009, pp. 1005-1009. http://dx.doi.org/10.3851/IMP1411
[45]	“Stanford HIV Drug Resistance Database,” 2013. http//hivdb.stanford.edu/pages/drugSummaries.html
[46]	A. M. Geretti, “Clinical Implication of HIV Drug Resistance to Nucleoside Reverse Transcriptase Inhibitors,” AIDS Reviews, Vol. 8, No. 4, 2006, pp. 210-220.
[47]	V. A. Johnson, C. Vincent, H. F. Gunthard, P. Roger, P. Deenan, S. Robert, A. M. Wensing and D. D. Richman, “2011 Update of the Drug Resistance Mutation in HIV1,” Topics in Antiviral Medicine, Vol. 19, No. 4, 2011, pp. 156-164.
[48]	E. P. Coakley, J. M. Gills and S. M. Hammer, “Phenotypic and Gonotypicrersistance Pattern of HIV-1 Isolate Derived from Individuals Treated with Diagnosing and Stavudine,” AIDS, Vol. 14, 2002, pp. F9-F15. http://dx.doi.org/10.1097/00002030-200001280-00002
[49]	R. K. Gupta, A. Hill, A. W. Sawyer, et al., “Virological Monitoring and Resistant to First-Line Highly Active Antiretroviral Therapy in Adults Infected with HIV-1 Treated under WHO Guidelines: A Systematic Review and Mental Analysis,” Lancet Infectious Diseases, Vol. 9, 2009, pp. 409-417. http://dx.doi.org/10.1016/S1473-3099(09)70136-7